About Inhibrx Biosciences, Inc. - Common Stock (INBX)
Inhibrx Biosciences Inc is a biotechnology company focused on the discovery and development of innovative therapeutic solutions for patients with cancer and other serious diseases. The company employs its proprietary platform to engineer novel protein-based therapeutics that target specific disease mechanisms, aiming to enhance the efficacy and safety of treatments. Through rigorous research and clinical trials, Inhibrx seeks to advance its drug candidates, offering hope for new options in the ever-evolving landscape of medical therapies. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets, for each share of Inhibrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets, for each share of Inhibrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms of the proposed transaction, for each Inhibrx share, Inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets.
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatment, the mortality rates remain high and essentially unchanged over the last two decades. Furthermore, even in the setting […]
